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Abstract
Hydrocephaly is a prevalent condition in all age groups. At present, the most frequent
strategies used to treat hydrocephaly are surgical shunting procedures, which are still
associated with multiple complications. The main goal of the medical therapy for the
lowering of high ventricular pressure is to avoid shunting or to reduce and decrease
intracranial pressure (ICP) until shunt surgery. Medications affect cerebrospinal fluid
dynamics by decreasing secretion or increasing reabsorption. Medical treatment for
manipulation of water balance or cerebrospinal fluid (CSF) production reduces mortality
in both infants and adults with neurological disorders. Medical treatment has an impor-
tant role in the management of hydrocephaly especially in patients not suitable for shunt
and in patients whom the shunt alone is not able to control the hydrocephaly. The
treatment is used to delay surgical intervention but is not effective in the long treatment
of chronic hydrocephaly.
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1. Introduction
Hydrocephaly is an increased volume of cerebrospinal fluid (CSF) in or around the brain that
can be produced by various disorders [1]. CSF accumulation mostly occurs within ventricles,
but the accumulation may occur in other sites of the brain. It can develop at any age, both in
infants and in adults [2]. The cumulative 5-year complication rate was reported approximately
48% in children and 27% in adults, in a large population-based analysis in California in the
1990s [3]. According to the studies, approximately 3.4 per 100,000 per year in the adult
population undergo a surgical procedure for hydrocephaly. In infants, symptoms include a
large and rapidly growing head, bulging, irritability, and seizures. In adults and children,
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symptoms are headache, difficulty in walking, lossing the ability in hard activities, decrease in
mental abilities, vomiting, and lethargy. A headache may even awaken the patient from sleep
in case of increased intracranial pressure (ICP). Papilledema is more common in adults than
children.
Hydrocephaly can be classified according to the site of CSF flow obstruction or impairment as
internal hydrocephaly CSF accumulation which occurs in ventricles and external hydrocephaly
in which the accumulation of CSF occurs in subarachnoid space in cerebral cortical surfaces.
Hydrocephaly is classified into two groups according to its cause: communicating and
noncommunicating hydrocephaly. In communicating hydrocephaly, CSF flows from lateral
ventricles into cerebral and spinal subarachnoid space (SAS). In contrast, noncommunicating
hydrocephaly flow of the CSF through ventricles is interrupted for any reason. The obstruction
of CSF flow in noncommunicating hydrocephaly may happen either internal or external to the
ventricles. On the other hand, the overproduction of CSF may cause an accumulation at any
site of the brain. Hydrocephaly can be classified according to the duration of development
into three groups, which are acute, subacute, and chronic hydrocephaly. Another classifica-
tion of hydrocephaly is the disorder into high-pressure and normal-pressure hydrocephaly
(NPH) [1–5].
2. Medical treatment options
Cerebrospinal fluid shunting is the standard treatment for hydrocephaly, but there are certain
medical treatment approaches alternatively applied alone or in combination with shunting.
Treatment of hydrocephaly depends on its cause. Medical treatment is used to delay surgical
procedures in hydrocephaly. Medical treatment is not effective in long-term treatment of
chronic hydrocephaly but can be resumed to balance CSF dynamics (production or absorption)
during this interim period. Medications include decreasing CSF secretion by the choroid plexus
(acetazolamide), increasing CSF reabsorption (isosorbide, furosemide), or osmotic diuretics
which increase water excretion and are used to reduce intracranial pressure (Table 1) [1, 2].
2.1. Reducing cerebrospinal fluid production
2.1.1. Carbonic anhydrase inhibitors
Carbonic anhydrases are a family of metalloenzymes present in the renal cortex, gastric
mucosa, pancreas, liver, lungs, ciliary body, and brain, which catalyze the reversible hydration
of carbon dioxide and bicarbonate. Thus, this allows to regulate intra- and extracellular con-
centrations of CO2, H
+, and HCO3
 [1, 6]. These enzymes are also found in the glia and the
choroid plexus which plays secretory roles in the brain. Enzyme concentration is greater than
the ciliary body in the choroid plexus [1, 6].
Complete choroid plexus carbonic anhydrase inhibition reduces cerebrospinal fluid (CSF)
production by 50%. Many studies have shown that inhibition of carbonic anhydrase reduces
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cerebrospinal fluid production. In clinical practice, the most frequently used drug which
inhibits carbonic anhydrase and treats hydrocephaly patients is acetazolamide (ACZ) [6–11].
2.1.1.1. Acetazolamide
Acetazolamide (2-acetylamino-1,3,4-thiadiazole-5-sulfonamide) is a sulphonamide derivative
with a potent inhibitory effect on carbonic anhydrase, which was first synthesized by Roblin
and Clapp in 1950 [12]. Acetazolamide has been used in the treatment of cardiac edema,
glaucoma, urinary alkalinization, metabolic alkalosis, and acute mountain sickness [1, 10, 13].
Numerous experimental and clinical studies have shown reduction in CSF production after
ACZ administration. Effective doses of acetazolamide, which penetrate the blood-brain barrier
to reach the choroid plexus and depress CSF flow, are on the order of 20 mg/kg [2, 6, 11, 14–18].
However, there is no standard dose of acetazolamide; the starting dose is 500 mg two times
daily and a maximum dose of 4 g twice daily [19]. Recommended starting dose in children is
25 mg/kg per day with a maximum dose of 100 mg/kg or 2 g per day [20]. Complete inhibition
of choroid plexus reduces CSF production by 50%, which was obtained after administration of
5–20 mg/kg of ACZ [6, 11].
In some cases, despite the reduction in CSF production, ACZ treatment could not reduce
intracranial pressure, on the contrary of increasing it. This unexpected effect may be due to an
indirect effect of ACZ on cerebral vessels and blood flow of the cerebrum [1].
Hypersensitivity especially sulfur allergy and hepatic failure are contraindications for ACZ
and also relatively contraindicated in patients with a history of renal stones [19]. An important
side effect of acetazolamide is the development of hyperchloraemic metabolic acidosis with
hypokalemia. Other adverse effects include dysgeusia, paresthesia, fatigue, nausea, diarrhea,
and polyuria [17]. These side effects are usually dose related. For this reason monitoring of
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electrolytes is suggested during acetazolamide treatment, and potassium and bicarbonate
replacement therapies are required for reducing the adverse effect of ACZ [1].
In expert opinion, acetazolamide is the most suitable drug alone or in combination with
furosemide for treatment of hydrocephaly [1].
2.1.2. Furosemide
Furosemide selectively inhibits sodium reabsorption in the nephron at the loop of Henle,
which is a potent loop diuretic used to treat high blood pressure, congestive heart failure, and
swelling due to excess body water and also used in hyperkalemia and acute renal failure [1, 10].
Studies have shown that furosemide reduces the production of cerebrospinal fluid by inhibiting
the transport of Cl to the cerebrospinal fluid [21–24]. In the medical treatment of hydrocephaly,
the usual dose of furosemide is 1 mg/kg/day divided into two doses/day [25, 26]. Adverse effects
of furosemide therapy are serum electrolyte disturbances, hypotension, and ototoxicity; for this
reason, electrolyte levels have to be followed closely [10].
2.1.3. Combined therapy of furosemide and acetazolamide
Studies have shown that combination therapy of furosemide and acetazolamide was not
effective in decreasing the frequency of shunting or death. Therefore, this therapy is not
recommended [2, 26–29].
2.2. Osmotic diuretics
The proximal tubule and descending limb of Henle’s loop are freely permeable to water.
Osmotic diuretic agents are freely filtered at the glomerulus, undergo minimal reabsorption
by the renal tubules causes water to be retained in these segments and promotes water
diuresis. Four osmotic diuretics are available: glycerin, isosorbide, mannitol, and urea; manni-
tol is the most commonly used in clinical practice and the most extensively studied. Osmotic
diuretics are used to increase water excretion and to promote prompt removal of renal toxins
and also are used to reduce intracranial pressure [10, 30].
2.2.1. Isosorbide
Isosorbide (1,4:3,6-dianhydro-d-glucitol) is an osmotic agent developed for the treatment of
glaucoma. It has also been shown to reduce the intracranial pressure [31, 32]. The single oral
dose of isosorbide significantly reduces intraventricular pressure. Multiple studies showed the
usual dose of isosorbide, which is 2–3 g/kg/day given at intervals of 6–12 h [33, 34].
Lorber et al. have studied the use of isosorbide in patients with various types of hydrocephaly;
they reported that patient did not require shunt insertions after prolonged medication
with isosorbide. But isosorbide did not replace than surgery and was less efficient than surgery
[34–36].
Lorber concluded that isosorbide was safe in a large number of patients; adverse effects were
less, and less frequent biochemical monitoring was required [34].
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Only recommend isosorbide for short-term treatment of hydrocephaly with constant surveil-
lance to prevent hypernatremic dehydration. However, osmotic agents are not preferred in the
treatment of hydrocephaly at present [1, 31, 33, 37].
2.2.2. Mannitol
Mannitol is a six-carbon alcohol with a molecular weight of 182. This osmotic agent is not
metabolized and is excreted by glomerular filtration, without any important tubular
reabsorption or secretion. Also, mannitol induces an increase in serum osmolality and an
osmotic gradient between the serum and intracranial compartment. Thus, removal of brain
water causes to reduce ICP. Mannitol has been widely used to reduce intracranial and intraoc-
ular pressures because of its osmotic diuretic action and presumed antioxidant properties for
many years. Mannitol is poorly absorbed from the gastrointestinal tract if administered orally;
it would cause osmotic diarrhea, so it must be given parenterally [10, 38–40].
A dose of 0.25–1 g/kg (20% solution) mannitol is administered intravenously and infused over
5 min. Intracranial pressure should fall in 60–90 min [1, 10]. In most cases, after the adminis-
tration of a bolus of mannitol, intracranial pressure rapidly decreases, but in some patients, it
can worsen intracranial hypertension [10].
The effect of mannitol in the treatment of hydrocephaly has been reported in only a few
studies. Hayden et al. showed that the administration of mannitol induces rapidly decreased
ICP, but this effect lasted only 3–4 h and was followed by a rebound of ICP above baseline [41].
Ma et al. showed that mannitol and corticosteroids represent an effective treatment approach
for patients with autoimmune diseases associated with hydrocephaly [42].
Mannitol produces a diuresis more than a natriuresis, and if free water losses are excessive,
hypernatremia and hyperkalemia may ensue [10].
2.2.3. Glycerol
Glycerol is an oral osmotic agent, reduces intracranial pressure in adults with brain tumors,
and was suggested as a possible agent for managing hydrocephaly [43]. On the contrary,
uncontrolled trials did not support its use. Glycerol had no effect in premature infants with
hydrocephaly and did not treat hydrocephaly in adults with metastatic brain cancer [44, 45].
2.3. Increasing CSF absorption
2.3.1. Glucocorticoids
Glucocorticoids have been used for decades in a range of neurological disorders associated
with raised intracranial pressure [2]. Experimental studies have shown that glucocorticoids
reduced CSF production and CSF flow [46, 47]. Glucocorticoids have also been used to reduce
the fibrosis in the subarachnoid compartment [2].
In intraventricular hemorrhage (IVH) cases, the blood clot in the ventricular system can




bacterial or carcinomatous meningitis, cerebrospinal fluid absorption can be reduced. Gluco-
corticoids can slow this inflammatory response after these conditions. However, steroids do
not inhibit fibroblast growth or collagen synthesis. Intrathecal or intravenous steroids have
been used to prevent or alleviate arachnoiditis with poor results [1].
Some studies have shown that in autoimmune diseases associated with hydrocephaly gluco-
corticoids have been beneficial and corticosteroids should be considered as first-line treatment
choice [42, 48–50].
3. Other treatment options
3.1. Prevention of inflammatory and fibrotic process
Intraventricular hemorrhage, subarachnoid hemorrhage, and infection (e.g., meningitis),
which can lead to restriction of CSF, are all associated with secondary inflammation and
fibrosis in the subarachnoid compartment. Although many mechanisms have been proposed
to explain the pathophysiology of hydrocephaly, it has not yet been fully elucidated. Common
theories: hemorrhage debris or clot obstruction of the CSF circulation of the arachnoid, sub-
arachnoid, and arachnoid fibrosis, inflammation, apoptosis, autophagia, and oxidative stress
[51–54].
3.2. Cerebrospinal fluid pathway modulation
Gliocytes play a destructive and curative role in the abundance of cytokines released when the
brain is exposed to various lesions [55]. It also contributes to the inflammatory side by causing
the structurally and functionally cleavage of the vegetative nervous system and glia cell which
join the blood-brain barrier [53]. Inflammation of CSF and fibrosis is one of the general features
of hydrocephaly and leads to a restriction in CSF flux. Conditions that may cause restriction
include intraventricular hemorrhage, subarachnoid hemorrhage, or infection (e.g., meningitis),
are all associated with secondary inflammation and fibrosis in the CSF tract, especially in the
subarachnoid compartment. In children, intraventricular hemorrhage and bacterial meningitis
are associated with meningeal fibrosis, which completely abolishes the subarachnoid space. In
subarachnoid hemorrhagic adults, inflammation occurs in the arachnoid villi during the first
week, and it is followed by collagen production [56]. Enzymatic resolution of intraventricular
or subarachnoid blood collections, intervention in the inflammatory process, and the produc-
tion of extracellular matrix molecules are the ways to reduce hydrocephaly development, and
investigation is still going on.
3.3. Thrombolytic therapy
Some researchers have conducted experimental studies to investigate the efficacy of thrombo-
lytic therapy in preventing posthemorrhagic hydrocephaly. In 1986, Pang et al. tested the
efficacy of fibrinolytic (urokinase; uPA) in the treatment of hydrocephaly for the first time
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and found that intraventricular administration of uPA effectively attenuated ventriculomegaly
[52]. Similarly, several empirical studies have shown that intraventricular tPA administration
is effective in preventing hydrocephaly after subarachnoid hemorrhage and regressing ven-
tricular dilatation [57]. However, the development of perihematomal edema after tPA admin-
istration has increased question mark on this treatment method. Meta-analyses for the
comparison of the uPA and tPA regarding the dissolution of the clot after intraventricular
hemorrhage were made [58, 59]. Studies have shown that both uPA and tPA cause a decrease
in ventricular volumes, but only uPA improves functional recovery significantly.
3.4. Anti-inflammatory therapy
There is a clear relationship between inflammation in the CSF tract and subsequent hydro-
cephaly development. Anti-inflammatory agents have been experimentally tested to prevent
hydrocephaly after meningitis and posthemorrhage. There are numerous studies showing that
corticosteroid therapy after acute bacterial meningitis significantly reduces hearing loss and
neuroleptic sequelae, but the effects on hydrocephaly development are not fully known. Some
studies have shown that the use of steroids does not change the likelihood of developing
hydrocephaly or that this risk can be elevated in children [60–62].
3.5. Vasoactive drugs
Nimodipine is widely used as a calcium channel blocker for the control of hypertension.
Experimental studies have shown that nimodipine reduces motor and cognitive function
impairment after hydrocephaly [63]. Clinical trials showed that nimodipine is safe, but there
is no definitive evidence for the effectiveness in the treatment of hydrocephaly. Magnesium, a
calcium antagonist, also has a weaker protective effect [64].
3.6. Antioxidative therapy
Mechanical factors and reduced white matter blood flow into axonal and oligodendroglial
damage can lead to neuropathophysiological damage [65]. Hypoxic changes in proteins of white
matter glial and endothelial cells have been found in hydrocephaly by immunohistochemical
detection of pimonidazole [66]. Antioxidant therapy is a potential pharmacological treatment for
oxidative stress that is associated with brain damage in hydrocephaly. Dietary supplementation
of antioxidants like oral coenzyme Q10 (CoQ10), ascorbic acid, glutathione, and lipoic acid in
humans and animals reduces oxidative stress by decreasing lipid peroxidation [67].
3.7. Neuron vs axon protection
Neuronal damage in the cortex has been attributed to the disturbed activity of the noradrenergic
and dopaminergic neuronal systems and synaptogenesis caused by hydrocephaly [68, 69]. Mor-
phological changes in the hydrocephalic brain with ventricular dilation occur most characteristi-
cally in the white matter [70]. Periventricular axons in hydrocephalic brains may sustain the
damage in some neurons. Studies on hydrocephaly demonstrated that hippocampal neurons




hydrocephaly affects developmental processes of cell genesis and myelination [68]. Potential
early therapeutics are antioxidative, anti-inflammatory, antiapoptotic, and anti-excitotoxic drugs
that can be used in neonatal hypoxic-ischemic brain injury. Memantine, a noncompetitive
NMDA receptor antagonist, protects neurons and axons [72]. The neuronal cytoskeleton has
been shown to play an important role in themaintenance of cytoplasmic morphology and axonal
transport [15]. The functional effects of early shunt placement have been reported to prevent
impairment of synaptogenesis and learning disability [73].
3.8. Cerebral stimulants
Bifemelane is a monoamine oxidase inhibitor used as an antidepressant and cerebral metabolic
activator to normalize norepinephrine in the striatum and cerebral cortex [74]. Methylpheni-
date acts by blocking the dopamine and norepinephrine transporters and was administered to
NPH patient at the dose of 20 mg after shunting improved cognitive performance and reduced
apathy [75]. In another case reports, patients with hydrocephaly and akinetic mutism
responded well to bromocriptine and ephedrine [76, 77]. An unshunted severe hydrocephaly
patient with self-injurious behavior responded well to trazodone (200 mg/day) [78].
4. Conclusions
Hydrocephaly can be defined briefly as the excess formation of cerebrospinal fluid (CSF)
leading to an increase in the fluid volume of ventricles and subarachnoid spaces of the brain
[1, 2]. Water is distributed in four compartments within the brain: (i) the intracellular space, (ii)
the interstitial space, (iii) the cerebral ventricles and subarachnoid spaces, and (iv) the cerebral
blood vessels. CSF flow obstruction in hydrocephaly leads to transependymal flow of water
and electrolytes from the enlarged ventricles into the interstitial space of the brain adjacent to
the ventricular wall which is called hydrocephalic edema [79]. The osmotic agents in these
patients increase serum osmolality by drawing fluid from the interstitial space into the capil-
laries and then out of the cranium to the general circulation. Currently used osmotic diuretics
for the treatment of hydrocephaly include isosorbide and mannitol. Fibrin can also deposit in
arachnoid villi that can block its openings which is resulted in reduced CSF absorption. This
can be ameliorated by the administration of fibrinolytic agents injected directly into the CSF or
ventricular system. Hydrocephaly secondary to an IVH has been managed with intraventricu-
lar fibrinolytic therapy, alone or in combination with carbonic anhydrase inhibitors. Another
situation is the reduction of CSF absorption that can be present in the acute period after
subarachnoid hemorrhage and bacterial or carcinomatous meningitis. Steroids can regulate
the inflammatory response after inflammation, but fibroblast growth or collagen synthesis
cannot be inhibited by steroids [2].
Hydrocephaly treatment can be classified as nonsurgical and surgical, which in turn can be
divided into nonshunting and shunting procedures. Nonsurgical treatment includes reducing
CSF formation, and the most common drugs used for this purpose are acetazolamide and
furosemide. Hydrocephaly secondary to intraventricular hemorrhage (IVH) has been treated
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by serial lumbar punctures [67] to maintain normal-pressure hydrocephaly. The aims of this
process are to reduce protein and blood in the CSF and thereby to prevent the formation of
fibrin. Nonshunting surgical options include endoscopic third ventriculostomy in CSF obstruc-
tions at, or distal to, the aqueduct and fenestration of the lamina terminals [80].
The major three mechanisms of medical treatment of patients with hydrocephaly are based on
(i) reducing CSF production, (ii) decreasing brain water content, and (iii) increasing CSF.
About two-thirds of CSF is formed at the choroid plexus, and the other third is formed in the
brain and spinal cord [80]. After the filtration of water across the choroidal epithelium, the
increased pressure of CSF then involves active transport of water and ions across the choroidal
sacs which are controlled mainly by Na+/K+ ATPase. Active secretion of water and ions by the
choroidal epithelium into the ventricles are controlled by the activity of carbonic anhydrase
[76]. Digoxin and ouabain are effective drugs that are used as Na+/K+ ATPase inhibitors [78].
Carbonic anhydrase inhibitors are effective drugs still used to decrease the rate of CSF produc-
tion in the choroid plexus. Loop diuretic agents, such as furosemide, have also been used to
reduce CSF formation.
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